Multicenter Phase II Study of Peritransplantation Immunosuppression Using ATG, Rituximab, Sirolimus and Mycophenolate Mofetil in Patient Receiving Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning With Fludarabine and Treosulfan

NCT01582048 Phase 2 TERMINATED

Feasibility and toxicity of peritransplantation immunosuppression with ATG, sirolimus, mycophenolate mofetil and rituximab in patients receiving mismatched allogeneic HCT after a reduced intensity conditioning regimen with fludarabine/treosulfan

Details

Lead sponsor	Prof. Dr. med. Wolfgang Bethge
Phase	Phase 2
Status	TERMINATED
Enrolment	9
Start date	2012-04
Completion	2016-08-17

Conditions

• Patients Receiving Mismatched Allogeneic HCT

Interventions

• immunosuppression

Primary outcomes

• Treatment related mortality — 12 months after HCT
• Treatment related mortality — 24 months after HCT

Countries

Germany